Global Alcoholic Hepatitis Treatment Market to Reach USD 5.3 Billion by 2033 at a 6.5% of CAGR

Global Alcoholic Hepatitis Treatment Market

According to a recent analysis by Future Market Insights (FMI), the global alcoholic hepatitis treatment market is set to experience substantial growth over the next decade, with the market value anticipated to reach US$ 5.3 billion by 2033, up from US$ 2.6 billion in 2022. This growth is primarily attributed to the increasing prevalence of liver disorders associated with alcohol consumption, coupled with the rising demand for effective therapeutic solutions to treat alcoholic hepatitis.

FMI’s report underscores several key factors contributing to the expansion of the alcoholic hepatitis treatment market, including advancements in medical therapies, increased healthcare awareness, and the growing focus on early intervention. The market is anticipated to benefit from the introduction of novel pharmacological treatments and supportive care methods aimed at improving patient outcomes and addressing the significant unmet needs within this segment.

Key Insights from FMI’s Alcoholic Hepatitis Treatment Market Survey:

• Market Growth and Demand: The alcoholic hepatitis treatment market is expected to grow at a robust rate as healthcare providers prioritize early diagnosis and effective intervention strategies.
• Therapeutic Advancements: Innovations in anti-inflammatory drugs, antioxidants, and immunomodulatory therapies are enhancing treatment options and improving patient outcomes, while new drug developments continue to drive the market forward.
• Regional Market Dynamics: North America is projected to maintain its leadership in the market, fueled by advanced healthcare infrastructure and high awareness levels, while Asia-Pacific is expected to experience significant growth due to increasing alcohol consumption and healthcare improvements.

Future Outlook

The global alcoholic hepatitis treatment market is on a strong growth trajectory as healthcare providers and pharmaceutical companies continue to address the pressing need for targeted therapies and enhanced patient care. FMI’s report indicates that investments in research and development are expected to facilitate new product launches and more effective treatment protocols, enabling improved quality of life for those affected by alcoholic hepatitis.

Global Alcoholic Hepatitis Treatment Industry Key Takeaways:

• Drug treatment is the leading segment as treatment among patients and professionals, and held about 88.3% market share in 2022, due to its non-invasive nature and high efficacy in patients.
• By route of administration, the oral segment is leading with a 78.2% market share in 2022 as oral medications are often the first-line treatment for alcoholic hepatitis because they are effective and relatively easy to administer.
• By distribution channel, institutional sales dominated the global alcoholic hepatitis treatment market withholding the total market share of about 55.9% by the end of 2022 as healthcare institutions such as hospitals, clinics, and long-term care facilities provide a wide range of services and treatments for patients with alcoholic hepatitis.
• By region, North America is leading in the global alcoholic hepatitis treatment market with a 39.9% market share in 2022 and is expected to continue to do so during the forecasted years due to the increasing prevalence of alcoholic hepatitis.

“Increasing adoption of stem cell therapies and growing awareness and diagnosis of alcoholic hepatitis to create the lucrative potential for the market in near future,” says an analyst at Future Market Insights (FMI).

Sales Analysis of Alcoholic Hepatitis Treatment Market from 2012 to 2022 Vs Market Outlook for 2023 to 2033

Sales of the market grew at a CAGR of 3.8% between 2012 and 2022. The alcoholic hepatitis treatment market contributes 15.0% revenue share to the global liver diseases treatment market which is US$ 17.5 Billion in 2022.

The market has been growing steadily in recent years and is expected to continue to do so in the coming years. The market is being driven by several factors, including an increased prevalence of liver diseases caused by alcohol consumption, a growing demand for effective treatments, and advancements in medical technology.

The primary driver of the market is the increasing prevalence of liver diseases caused by alcohol consumption. As more people consume alcohol and in higher quantities, the incidence of liver diseases such as alcoholic hepatitis has been on the rise.

Governments are providing funding for research into the causes, prevention, and treatment of liver diseases caused by alcohol consumption. This funding is driving the development of new therapies and technologies that are more effective in treating alcoholic hepatitis. Governments are implementing awareness campaigns aimed at educating the public about the risks associated with excessive alcohol consumption and the importance of early diagnosis and treatment. These campaigns are increasing public awareness of the disease and driving demand for effective treatments.

Therefore, favorable government initiatives are playing an important role in driving the growth of the market by increasing public awareness of the disease, improving access to healthcare, and supporting the development of new therapies and technologies.

Considering this, FMI expects the global market is projected to expand at a CAGR of 6.5% through the forecasted years.

Competitive Landscape

Key manufacturers in the alcoholic hepatitis treatment market employ a range of strategies to gain a competitive edge and increase their market share. These strategies include developing new and innovative drugs, acquisitions and expansions, strategic collaborations, pricing strategies, and regulatory compliance.

For instance:

• In March 2022, Pfizer Inc. announced that it acquired Arena Pharmaceuticals, a company that develops new potential treatments for immuno-inflammatory diseases.
• In September 2022, F. Hoffmann-La Roche Ltd entered into a definitive agreement to acquire Good Therapeutics, a privately held biopharmaceutical company.
• In June 2022, Hikma Pharmaceuticals PLC expanded its presence in France with the opening of Hikma France S.A.S. (Hikma France).

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the alcoholic hepatitis treatment market space, which are available in the full report

Key Companies Profiled

F. Hoffmann-La Roche Ltd (Genentech, Inc); Teva Pharmaceuticals; Pfizer; Alkermes, Inc; Viatris Inc; Merck KGaA; Sun Pharmaceutical Industries Ltd; Hikma Pharmaceuticals PLC; H. Lundbeck A/S; Mallinckrodt; Glenmark Pharmaceuticals U.S. Inc; Torrent Pharmaceuticals Ltd; Wellona Pharma

A Comprehensive Full Report

Key Segments Covered in Alcoholic Hepatitis Treatment Industry Research

By Treatment:

• Drug Treatment
  • Acamprosate
  • Naltrexone
  • Pentoxifylline
  • Infliximab
  • Corticosteroids
  • Benzodiazepines
  • Nutritional Supplements
  • Others
• Stem Cell Therapy

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Institutional Sales
  • Hospitals
  • Stem Cell Centers
  • Specialized Clinics
  • Cancer Research Institutes
• Retail Sales
  • Retail Pharmacies
  • E- Commerce/Mail Order Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube